Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botensilimab, Balstilimab and Regorafenib in MSS CRC
NCT06575725Phase 2Withdrawn
- Sponsor
- City of Hope
- Start
- Nov 2024
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of botensilimab in colorectal cancer (CRC), sponsored by City of Hope. Planned start Nov 2024; status: withdrawn.
02
Drugs
botensilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06575725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575725.